TRADITIONAL POSTER - ismrm

Poster Sessions
MWF. While mean T 1 and GMT 2 have slightly better reproducibility, MWF provides a specific measure of brain myelin content, and is hence ideal for
assessing neuroprotective and remyelination strategies.
2106. 1H-MRS and Water Proton T1 Investigations of New Lesions in Relapse Remitting Multiple Sclerosis
Madeleine Hodgson 1 , Cornelia Laule 1,2 , Irene Vavasour 1,2 , Burkhard Mädler 1 , Alex MacKay 1,2
1 Physics, University of British Columbia, Vancouver, British Columbia, Canada; 2 Radiology, University of British Columbia,
Vancouver, British Columbia, Canada
Little is known about the pathological evolution of acute MS lesions. Using 1H-MRS one can measure changes in metabolites such as n-acetyl-aspartate
(NAA), which may become altered in MS. We used 1H-MRS and water proton T1 measurements to investigate the time-course of biochemical changes
occurring in new MS lesions. Multi-voxel 1H-MRS data was acquired monthly from 20 Relapsing-Remitting MS subjects. Metabolite and water proton T1
changes for the same volume were investigated Lesions exhibited a significant decrease in NAA and a significant increase in mean T1, compared to normal
appearing white matter, 2 months before lesion appearance on conventional imaging.
2107. 1H-MRS Study of Secondary Progressive MS Patients Followed Over 2 Years in the Dirucotide
(MBP8298) Placebo Controlled Study
Madeleine Hodgson 1 , Cornelia Laule 1,2 , Irene Vavasour 1,2 , David Li 2 , Yinshan Zhao 3 , Tony Traboulsee 3 ,
Joel Oger 3 , Alex MacKay 1,2
1 Physics, University of British Columbia, Vancouver, British Columbia, Canada; 2 Radiology, University of British Columbia,
Vancouver, British Columbia, Canada; 3 Medicine, University of British Columbia, Vancouver, British Columbia, Canada
1H-MRS is a useful technique for evaluating demyelination and axonal integrity and thus can be used to monitor disease progression in Multiple Sclerosis
(MS). Dirucotide (MBP8298) has exhibited potential as a treatment for Secondary Progressive MS (SPMS) to slow disease progression. The effects of
Dirucotide were investigated using 1H-MRS in a single centre, double-blinded MRI substudy with a placebo control. There is no change observed in
important metabolites in either of the cohorts over a two-year period, which is perhaps not surprising given that Dirucotide did not meet primary endpoints in
the MAESTRO-01 Phase III trial.
2108. In Vivo Measurement of Glutathione (GSH) in the Human Brain with Secondary Progressive Multiple
Sclerosis Using Selective Multiple Quantum Chemical Shift Imaging of GSH
In-Young Choi 1,2 , Sang-Pil Lee 1,3 , Sharon G. Lynch 4
1 Hoglund Brain Imaging Center, University of Kansas Medical Center, Kansas City, KS, United States; 2 Department of Neurology,
Molecular & Integrative Physiology, University of Kansas Medical Center, Kansas City, KS, United States; 3 Department of Molecular
& Integrative Physiology, University of Kansas Medical Center, Kansas City, KS, United States; 4 Department of Neurology,
University of Kansas Medical Center, Kansas City, KS, United States
Oxidative stress has been implicated in multiple sclerosis (MS), a chronic inflammatory disease with the presence of a neurodegenerative process
particularly in progressive MS. However, the effects of oxidative stress in MS have not been well described in the living human brain. In this study, we
measured the cerebral GSH levels in the patients with secondary progressive MS (SPMS) using doubly selective multiple quantum GSH CSI. The GSH
levels were significantly lower in the SPMS patients compared with those in the age- and gender-matched healthy controls, indicating the presence of
increased oxidative stress in the absence of measurable inflammation.
2109. Quantitative Venous Vasculature Assessment on Susceptibility-Weighted Imaging Reflects Presence of
Severe Chronic Venous Insufficiency in the Brain Parenchyma of Multiple Sclerosis Patients. a Case-Control
Study
Guy U. Poloni 1 , Paolo Zamboni 2 , E. Mark Haacke 3 , Stefano Bastianello 4 , Michael G. Dwyer 1 , Niels
Bergsland 5 , Claudiu V. Schirda 1 , David Wack 1 , Christopher R. Magnano 1 , Bianca Weinstock-Guttman 6 ,
Fabrizio Salvi 2 , David Hojnacki 6 , Robert Zivadinov 1
1 University at Buffalo, Buffalo Neuroimaging Analysis Center, Buffalo, NY, United States; 2 University of Ferrera- Bellaria
Neurosciences, Vascular Diseases Center, Ferrera, Italy; 3 Radiology, Wayne State University, Detroit, MI, United States; 4 Institu
Neurologico Casimiro Mondino, Neuroradiology Unit, Pavia, Italy; 5 University at Buffalo, Buffalo Neuroimaging Analysis Center,
Buffalo, United States; 6 University at Buffalo, The Jacobs Neurological Institute, Buffalo, NY, United States
To develop an objective method for quantifying venous vasculature in brain parenchyma on susceptibility-weighted imaging (SWI). To apply this technique
in multiple sclerosis (MS) patients and in healthy controls (HC).
2110. A Semi-Automated Analysis Pipeline for Reproducible SWI Analysis of Multiple Sclerosis Pathology
Michael G. Dwyer 1 , Niels Bergsland 2 , Claudiu Schirda 2 , Mari Heininen-Brown, Ellen Carl, David Wack,
Guy U. Poloni, Robert Zivadinov 3
1 Buffalo Neuroimaging Analysis Center; 2 University at Buffalo, Buffalo Neuroimaging Analysis Center, Buffalo, NY, United States;
3 Neurology, Buffalo Neuroimaging Analysis Center, Buffalo , NY , United States
Susceptibility-weighted imaging (SWI) has gained much interest recently as a sensitive means for detecting iron deposition in a variety of diseases, including
multiple sclerosis (SM). We propose a fast and reproducible analysis pipeline to extract detailed quantitative SWI data and to combine it with other
established indicators of disease state (including magnetization transfer and perfusion imaging).